Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 4/20 | 0.67 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.67 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.67 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.67 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.67 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.67 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.67 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.67 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.67 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.67 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | BRD4 | O60885 | 1/20 | 0.67 |
| ▸ | NCOR1 | O75376 | 1/20 | 0.67 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.67 |
| ▸ | EGFR | P00533 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | LTA4H | P09960 | 1/20 | 0.67 |
| ▸ | NR0B1 | P51843 | 1/20 | 0.67 |
| ▸ | PLK1 | P53350 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1689206 | 0.91 | EPHX2 (0.68) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL9235727 | 0.84 | HDAC4 (0.61) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL27538195 | 0.82 | EPHX2 (0.63) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL175602 | 0.82 | EPHX2 (0.63) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL23055007 | 0.82 | HDAC1 (0.96) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL12659217 | 0.82 | HDAC1 (0.89) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL307290 | 0.81 | KMT2A (0.61) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL19026946 | 0.81 | L3MBTL1 (0.75) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL19026741 | 0.81 | HDAC4 (0.58) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL8261596 | 0.80 | HDAC1 (1.00) | HDAC4HDAC1HDAC7HDAC11HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018015493-A1 | METAL COMPLEXES HAVING THERAPEUTIC APPLICATIONS | ROYAL COLLEGE OF SURGEONS IN IRELAND (IE) | 2018-01-25 | — | — | WO | disclosed |
| US-20170158778-A1 | ANTI-KIT ANTIBODIES AND USES THEREOF | CELLDEX THERAPEUTICS, INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-9605081-B2 | Polynucleotides encoding anti-kit antibodies | CELLDEX THERAPEUTICS, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20170073422-A1 | ANTI-KIT ANTIBODIES AND USES THEREOF | KOLLTAN, LLC | 2017-03-16 | — | — | US | disclosed |
| US-9540443-B2 | Anti-kit antibodies | KOLLTAN PHARMACEUTICALS, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20160311924-A1 | ANTI-KIT ANTIBODIES AND USES THEREOF | KOLLTAN, LLC | 2016-10-27 | — | — | US | disclosed |
| US-9334332-B2 | Anti-kit antibodies | KOLLTAN PHARMACEUTICALS, INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-20140065168-A1 | ANTI-KIT ANTIBODIES AND USES THEREOF | KOLLTAN PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140056905-A1 | ANTI-KIT ANTIBODIES AND USES THEREOF | KOLLTAN PHARMACEUTICALS, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| WO-2012103165-A2 | ANTI-KIT ANTIBODIES AND USES THEREOF | KOLLTAN PHARMACEUTICALS, INC. (US) | 2012-08-02 | — | — | WO | disclosed |
| US-7399787-B2 | Methods of treating cancer with HDAC inhibitors | MERCK HDAC RESEARCH, LLC (US) | 2008-07-15 | — | — | US | disclosed |
| US-20080119562-A1 | Methods of Inducing Terminal Differentiation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-05-22 | — | — | US | disclosed |
| US-7375137-B2 | Methods of treating cancer with HDAC inhibitors | MERCK HDAC RESEARCH, LLC (US) | 2008-05-20 | — | — | US | disclosed |
| US-20080114069-A1 | Methods of inducing terminal differentiation | RICHON VICTORIA M | 2008-05-15 | — | — | US | disclosed |
| US-20070190022-A1 | Combination methods of treating cancer | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-08-16 | — | — | US | disclosed |
| US-20070060614-A1 | Methods of treating cancer with hdac inhibitors | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-03-15 | — | — | US | disclosed |
| US-20060167103-A1 | Methods of treating cancer with HDAC inhibitors | ATON PHARMA, INC. (US) | 2006-07-27 | — | — | US | disclosed |
| US-20040132825-A1 | Methods of treating cancer with HDAC inhibitors | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2004-07-08 | — | — | US | disclosed |
| US-20040127523-A1 | safe, daily dosing regimen of histone deacetylase (HDAC) inhibitors having favorable pharmacokinetic profiles such as high bioavailability and surprisingly give rise to high blood levels of the active compounds over an extended period of time | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2004-07-01 | — | — | US | disclosed |
| WO-2003075839-A2 | METHODS OF INDUCING TERMINAL DIFFERENTIATION | ATON PHARMA, INC. (US) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167103-A1 | Methods of treating cancer with HDAC inhibitors | HDAC5, HDAC1, HDAC4 | HDAC4 3/4885HDAC1 2/4885HDAC7 5/4885 |
| US-20080119562-A1 | Methods of Inducing Terminal Differentiation | HDAC3, HDAC1, HDAC5 | HDAC4 5/4885HDAC1 2/4885HDAC7 6/4885 |
| US-20040127523-A1 | safe, daily dosing regimen of histone deacetylase (HDAC) inhibitors having favorable pharmacokinetic profiles such as high bioavailability and surprisingly give rise to high blood levels of the active compounds over an extended period of time | HDAC1, HDAC5, HDAC9 | HDAC4 5/4885HDAC1 1/4885HDAC7 10/4885 |
| US-20040132825-A1 | Methods of treating cancer with HDAC inhibitors | HDAC5, HDAC9, HDAC1 | HDAC4 4/4885HDAC1 3/4885HDAC7 7/4885 |
| US-20070060614-A1 | Methods of treating cancer with hdac inhibitors | HDAC5, BCL6, HDAC9 | HDAC4 4/4885HDAC1 5/4885HDAC7 9/4885 |
| US-20160311924-A1 | ANTI-KIT ANTIBODIES AND USES THEREOF | KIT, CD2BP2, FAM20C | HDAC4 3820/4885HDAC1 3779/4885HDAC7 3346/4885 |
| US-20080114069-A1 | Methods of inducing terminal differentiation | HDAC3, HDAC1, HDAC5 | HDAC4 5/4885HDAC1 2/4885HDAC7 6/4885 |
| US-20070190022-A1 | Combination methods of treating cancer | HDAC5, HDAC1, HDAC4 | HDAC4 3/4885HDAC1 2/4885HDAC7 9/4885 |
| US-20140056905-A1 | ANTI-KIT ANTIBODIES AND USES THEREOF | KIT, CD2BP2, FAM20C | HDAC4 3910/4885HDAC1 3949/4885HDAC7 3517/4885 |
| US-20140065168-A1 | ANTI-KIT ANTIBODIES AND USES THEREOF | KIT, CD2BP2, FAM20C | HDAC4 3820/4885HDAC1 3779/4885HDAC7 3346/4885 |
| US-20170158778-A1 | ANTI-KIT ANTIBODIES AND USES THEREOF | KIT, CD2BP2, FAM20C | HDAC4 3820/4885HDAC1 3779/4885HDAC7 3346/4885 |
| US-20170073422-A1 | ANTI-KIT ANTIBODIES AND USES THEREOF | KIT, CD2BP2, FAM20C | HDAC4 3910/4885HDAC1 3949/4885HDAC7 3517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.